More diagnoses to drive celiac disease market growth through decade

GlobalData study finds current drug pipeline weak

LONDON — The global market for celiac disease is expected to grow substantially over the decade as more people are diagnosed with the condition, according to a new report.

The report, by British market research firm GlobalData, found that the global celiac disease therapeutics market would be worth more than $512 million by 2017 and $664.4 million by 2019.

The firm noted that while people with celiac disease can treat it with a gluten-free diet, such diets are relatively expensive, limit nutritional variety and often restrict social activities, thus creating a significant unmet need for nondietary therapies.

The current drug pipeline is weak, the firm said, with no drugs in phase-3 clinical trials and only two in phase-2 trials that may not enter the market until later in the decade.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Recommended stories

Login or Register to post a comment.